PriceTargets.com logo

Regeneron Pharmaceuticals - REGN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $973.13
  • Forecasted Upside: 52.02%
  • Number of Analysts: 25
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 16 Buy Ratings
  • 2 Strong Buy Ratings
$640.14 As of 03/26/2025 05:00 PM ET
▲ +6 (0.95%)

This chart shows the closing price for REGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$640.14Closing price on 03/26/25:
Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

Analyst Price Target is $973.13
▲ +52.02% Upside Potential
This price target is based on 25 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $973.13, with a high forecast of $1,300.00 and a low forecast of $165.00. The average price target represents a 52.02% upside from the last price of $640.14.

This chart shows the closing price for REGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$165$454$743$1.03k$1.32kClosing price on 03/26/25: $640.14High$1.30kAverage$973.13Low$165.00




Current Consensus is Moderate Buy

The current consensus among 25 contributing investment analysts is to moderate buy stock in Regeneron Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 19 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
10/4/2023
  • 0 strong buy ratings
  • 19 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 1 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/30/2024
  • 1 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/28/2024
  • 1 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2024
  • 2 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
2/25/2025
  • 2 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/27/2025

Latest Recommendations

  • 2 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/5/2025Leerink PartnrsUpgradeHold ➝ Strong-Buy
2/5/2025Robert W. BairdLower TargetNeutral ➝ Neutral$940.00 ➝ $759.00
2/5/2025Leerink PartnersUpgradeMarket Perform ➝ Outperform$762.00 ➝ $834.00
2/4/2025Leerink PartnersLower TargetMarket Perform ➝ Market Perform$980.00 ➝ $862.00
2/4/2025TD CowenLower TargetBuy ➝ Buy$1,230.00 ➝ $1,030.00
2/4/2025BMO Capital MarketsLower TargetOverweight ➝ Overweight$950.00 ➝ $903.00
2/4/2025Bernstein BankLower Target$1,070.00 ➝ $1,000.00
1/28/2025CitigroupLower TargetNeutral ➝ Neutral$795.00 ➝ $750.00
1/27/2025Piper SandlerLower TargetOverweight ➝ Overweight$1,195.00 ➝ $1,013.00
1/16/2025UBS GroupDowngradeBuy ➝ Neutral$1,130.00 ➝ $738.00
1/14/2025CitigroupLower TargetNeutral ➝ Neutral$895.00 ➝ $795.00
1/10/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$1,050.00 ➝ $900.00
1/8/2025Truist FinancialLower TargetBuy ➝ Buy$1,126.00 ➝ $1,004.00
1/7/2025Sanford C. BernsteinLower TargetOutperform ➝ Outperform$1,110.00 ➝ $1,070.00
12/17/2024Canaccord Genuity GroupDowngradeStrong-Buy ➝ Hold
12/17/2024Canaccord Genuity GroupInitiated CoverageStrong-Buy ➝ Hold$165.00
12/10/2024Bank of AmericaReiterated RatingUnderperform$565.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$1,150.00
11/14/2024Wolfe ResearchUpgradeStrong-Buy
11/14/2024CitigroupInitiated CoverageNeutral$895.00
11/13/2024CitigroupUpgradeHold
11/6/2024OppenheimerLower TargetOutperform ➝ Outperform$1,150.00 ➝ $1,000.00
11/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$1,260.00 ➝ $1,215.00
11/1/2024Morgan StanleyLower TargetOverweight ➝ Overweight$1,235.00 ➝ $1,184.00
11/1/2024BarclaysLower TargetOverweight ➝ Overweight$1,080.00 ➝ $1,065.00
11/1/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$1,300.00 ➝ $1,190.00
11/1/2024Truist FinancialLower TargetBuy ➝ Buy$1,137.00 ➝ $1,126.00
11/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$1,242.00 ➝ $1,195.00
10/24/2024Evercore ISILower TargetOutperform ➝ Outperform$1,250.00 ➝ $1,175.00
10/24/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$1,200.00 ➝ $1,150.00
10/23/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$1,015.00 ➝ $1,015.00
10/23/2024BarclaysLower TargetOverweight ➝ Overweight$1,220.00 ➝ $1,080.00
10/22/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$1,200.00 ➝ $1,050.00
10/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,260.00 ➝ $1,260.00
10/16/2024Truist FinancialLower TargetBuy ➝ Buy$1,200.00 ➝ $1,137.00
10/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,252.00 ➝ $1,260.00
9/24/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
9/24/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$1,282.00 ➝ $1,252.00
9/24/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$1,300.00 ➝ $1,300.00
9/24/2024Truist FinancialReiterated RatingBuy ➝ Buy$1,200.00 ➝ $1,200.00
9/24/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$1,175.00 ➝ $1,077.00
9/23/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$1,200.00 ➝ $1,200.00
9/17/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,282.00 ➝ $1,282.00
9/16/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$1,015.00 ➝ $1,015.00
9/9/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$1,015.00 ➝ $1,015.00
9/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,250.00 ➝ $1,250.00
8/23/2024Piper SandlerBoost TargetOverweight ➝ Overweight$1,166.00 ➝ $1,242.00
8/2/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,232.00 ➝ $1,240.00
8/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$1,150.00 ➝ $1,200.00
8/2/2024GuggenheimBoost TargetBuy ➝ Buy$1,180.00 ➝ $1,300.00
8/2/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$1,125.00 ➝ $1,200.00
8/2/2024BarclaysBoost TargetOverweight ➝ Overweight$1,200.00 ➝ $1,220.00
8/2/2024Truist FinancialReiterated RatingBuy ➝ Buy$1,135.00 ➝ $1,200.00
7/23/2024TD CowenBoost TargetBuy ➝ Buy$1,030.00 ➝ $1,200.00
7/22/2024Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$925.00 ➝ $1,000.00
7/19/2024Piper SandlerBoost TargetOverweight ➝ Overweight$1,000.00 ➝ $1,166.00
7/18/2024GuggenheimBoost TargetBuy ➝ Buy$1,040.00 ➝ $1,180.00
7/11/2024Morgan StanleyLower TargetOverweight ➝ Overweight$1,183.00 ➝ $1,182.00
7/10/2024BarclaysBoost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,200.00
6/27/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$1,152.00 ➝ $1,152.00
6/25/2024ArgusBoost TargetBuy ➝ Buy$1,060.00 ➝ $1,170.00
6/24/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,229.00 ➝ $1,229.00
6/17/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,150.00
6/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,200.00 ➝ $1,229.00
6/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,185.00 ➝ $1,200.00
5/14/2024Evercore ISIInitiated CoverageOutperform$1,150.00
5/13/2024Evercore ISIUpgradeStrong-Buy
5/3/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$925.00
4/24/2024TD CowenBoost TargetBuy ➝ Buy$1,020.00 ➝ $1,030.00
4/17/2024UBS GroupBoost TargetBuy ➝ Buy$1,090.00 ➝ $1,099.00
4/15/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$925.00
4/12/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$710.00 ➝ $720.00
4/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,189.00
4/3/2024Truist FinancialReiterated RatingBuy ➝ Buy$1,135.00
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$1,135.00
3/13/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$1,104.00 ➝ $1,115.00
3/12/2024Sanford C. BernsteinInitiated CoverageOutperform$1,125.00
2/27/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,096.00 ➝ $1,184.00
2/6/2024Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$850.00 ➝ $925.00
2/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$1,076.00 ➝ $1,110.00
2/5/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$1,055.00 ➝ $1,082.00
1/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$1,076.00
1/23/2024BarclaysBoost TargetOverweight ➝ Overweight$935.00 ➝ $1,020.00
1/12/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$884.00 ➝ $1,076.00
1/9/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$850.00
12/18/2023Truist FinancialReiterated RatingBuy ➝ Buy$1,045.00
12/6/2023TD CowenBoost TargetOutperform ➝ Outperform$900.00 ➝ $1,000.00
11/28/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$935.00 ➝ $937.00
11/28/2023Truist FinancialReiterated RatingBuy ➝ Buy$1,045.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$800.00
11/3/2023Piper SandlerBoost TargetOverweight ➝ Overweight$885.00 ➝ $895.00
11/3/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$847.00 ➝ $837.00
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$915.00 ➝ $914.00
11/3/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$950.00
10/16/2023Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$800.00 ➝ $850.00
10/12/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$833.00 ➝ $847.00
10/11/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$912.00 ➝ $915.00
9/29/2023Bank of AmericaBoost Target$665.00 ➝ $680.00
9/21/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$800.00
9/15/2023ArgusBoost TargetBuy ➝ Buy$825.00 ➝ $920.00
9/15/2023Westpark CapitalInitiated CoverageHold
8/21/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$720.00 ➝ $992.00
8/21/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$720.00 ➝ $992.00
8/21/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$820.00 ➝ $830.00
8/21/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$960.00 ➝ $985.00
8/21/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$875.00 ➝ $980.00
8/21/2023OppenheimerBoost TargetOutperform ➝ Market Perform$950.00 ➝ $1,050.00
8/21/2023BarclaysBoost TargetOverweight ➝ Overweight$900.00 ➝ $925.00
8/18/2023Canaccord Genuity GroupReiterated RatingHold ➝ Hold$720.00
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$1,045.00
8/7/2023BarclaysBoost TargetOverweight ➝ Overweight$888.00 ➝ $900.00
8/4/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$897.00 ➝ $912.00
8/4/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$818.00 ➝ $820.00
8/4/2023OppenheimerBoost TargetOutperform ➝ Outperform$900.00 ➝ $950.00
7/18/2023BMO Capital MarketsLower Target$1,040.00 ➝ $960.00
7/17/2023GuggenheimLower Target$935.00 ➝ $900.00
6/28/202322nd Century GroupReiterated RatingDowngrade
6/28/2023500.comReiterated RatingMaintains
6/28/2023VNET GroupReiterated RatingDowngrade
6/28/2023Truist FinancialLower Target$1,050.00 ➝ $1,045.00
6/28/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$953.00 ➝ $720.00
6/28/2023Royal Bank of CanadaLower Target$816.00 ➝ $789.00
6/28/2023Robert W. BairdLower Target$800.00 ➝ $760.00
6/28/2023Wells Fargo & CompanyLower Target$915.00 ➝ $875.00
6/28/2023BarclaysLower Target$915.00 ➝ $888.00
6/9/2023Royal Bank of CanadaBoost Target$811.00 ➝ $816.00
5/8/2023GuggenheimLower Target$960.00 ➝ $935.00
5/5/2023888Reiterated RatingMaintains
5/5/2023Morgan StanleyBoost Target$880.00 ➝ $927.00
5/5/2023SVB SecuritiesLower Target$976.00 ➝ $895.00
5/3/2023Truist FinancialBoost Target$856.00 ➝ $1,050.00
4/20/2023TD CowenBoost TargetOutperform$875.00 ➝ $885.00
4/12/2023Morgan StanleyLower Target$883.00 ➝ $880.00
3/31/2023JPMorgan Chase & Co.Boost TargetOverweight$900.00 ➝ $950.00
3/30/2023Jefferies Financial GroupBoost Target$925.00 ➝ $940.00
3/29/2023Bank of AmericaBoost TargetUnderperform$605.00 ➝ $650.00
3/28/2023Erste Group BankReiterated RatingBuy
3/27/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform
3/27/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$834.00 ➝ $976.00
3/24/2023BMO Capital MarketsBoost Target$1,025.00 ➝ $1,040.00
3/24/2023Wells Fargo & CompanyBoost TargetOverweight$860.00 ➝ $915.00
3/24/2023Robert W. BairdBoost TargetNeutral$756.00 ➝ $800.00
3/24/2023BarclaysBoost TargetOverweight$815.00 ➝ $915.00
3/24/2023Jefferies Financial GroupUpgradeHold ➝ Buy$675.00 ➝ $925.00
3/23/2023Raymond JamesUpgradeUnderperform ➝ Market Perform
3/23/2023EF Hutton Acquisition Co. IBoost TargetBuy$853.00 ➝ $862.00
3/20/2023Royal Bank of CanadaLower Target$806.00 ➝ $802.00
3/14/2023BMO Capital MarketsBoost TargetOutperform$1,001.00 ➝ $1,025.00
3/9/2023Royal Bank of CanadaBoost TargetSector Perform$787.00 ➝ $806.00
2/24/2023EF Hutton Acquisition Co. IReiterated RatingBuy$853.00
2/17/2023Wells Fargo & CompanyBoost TargetOverweight$800.00 ➝ $860.00
2/8/2023EF Hutton Acquisition Co. IBoost TargetBuy$851.00 ➝ $853.00
2/6/2023Royal Bank of CanadaLower TargetSector Perform$789.00 ➝ $787.00
2/6/2023Leerink PartnersBoost TargetMarket Perform$770.00 ➝ $834.00
2/6/2023Robert W. BairdBoost Target$670.00 ➝ $756.00
1/30/2023CowenUpgradeMarket Perform ➝ Outperform$775.00 ➝ $875.00
1/30/2023CowenUpgradeMarket Perform ➝ Outperform$775.00 ➝ $875.00
1/24/2023Morgan StanleyBoost TargetOverweight$868.00 ➝ $873.00
1/20/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$850.00
1/11/2023EF Hutton Acquisition Co. IReiterated RatingBuy$851.00
11/11/2022GuggenheimLower TargetBuy$925.00 ➝ $915.00
11/9/2022Truist FinancialBoost Target$790.00 ➝ $856.00
11/4/2022Morgan StanleyBoost TargetOverweight$851.00 ➝ $868.00
11/4/2022Leerink PartnersBoost TargetMarket Perform$756.00 ➝ $770.00
11/3/2022Piper SandlerLower TargetOverweight$775.00 ➝ $765.00
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$851.00
10/26/2022Raymond JamesDowngradeMarket Perform ➝ Underperform
10/20/2022CowenBoost Target$655.00 ➝ $750.00
10/20/2022CowenBoost TargetMarket Perform$655.00 ➝ $750.00
10/3/2022The Goldman Sachs GroupBoost TargetBuy$796.00 ➝ $970.00
9/16/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$700.00 ➝ $750.00
9/13/2022Piper SandlerBoost TargetOverweight$692.00 ➝ $775.00
9/12/2022GuggenheimBoost Target$740.00 ➝ $925.00
9/12/2022Wells Fargo & CompanyBoost TargetOverweight$735.00 ➝ $800.00
9/9/2022Truist FinancialBoost Target$718.00 ➝ $790.00
9/9/2022Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$630.00 ➝ $756.00
9/9/2022BarclaysBoost TargetOverweight$735.00 ➝ $815.00
9/9/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$625.00 ➝ $851.00
9/8/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold$536.00 ➝ $675.00
8/9/2022CowenBoost Target$655.00
8/4/2022BMO Capital MarketsBoost TargetOutperform$757.00 ➝ $788.00
8/4/2022Morgan StanleyBoost TargetEqual Weight$619.00 ➝ $625.00
7/25/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$630.00
7/20/2022CowenBoost TargetMarket Perform$635.00 ➝ $645.00
7/20/2022CowenBoost Target$635.00 ➝ $645.00
7/15/2022Morgan StanleyBoost TargetEqual Weight$610.00 ➝ $619.00
7/12/2022Cantor FitzgeraldInitiated CoverageNeutral$625.00
6/20/2022Evercore ISISet Target$635.00
6/17/2022Jefferies Financial GroupDowngradeSell$536.00
6/6/2022Jefferies Financial GroupInitiated CoverageUnderperform$536.00
6/3/2022Wells Fargo & CompanyLower TargetOverweight$750.00 ➝ $735.00
6/3/2022Morgan StanleyLower TargetEqual Weight$620.00 ➝ $610.00
5/31/2022ArgusBoost TargetBuy$680.00 ➝ $760.00
5/23/2022Leerink PartnersInitiated CoverageOutperform$738.00
4/20/2022CowenBoost Target$640.00 ➝ $645.00
4/20/2022CowenBoost Target$640.00 ➝ $645.00
4/12/2022Morgan StanleyBoost TargetEqual Weight$605.00 ➝ $632.00
4/12/2022BarclaysBoost TargetOverweight$700.00 ➝ $745.00
2/11/2022BMO Capital MarketsReiterated RatingBuy$780.00
2/8/2022Truist FinancialLower TargetBuy$754.00 ➝ $728.00
2/8/2022OppenheimerLower TargetOutperform$825.00 ➝ $775.00
2/7/2022Morgan StanleyBoost TargetEqual Weight$585.00 ➝ $605.00
2/4/2022BMO Capital MarketsReiterated RatingBuy$780.00
2/4/2022Piper SandlerBoost TargetOverweight ➝ Overweight$690.00 ➝ $692.00
1/31/2022Truist FinancialLower TargetBuy$756.00 ➝ $754.00
1/18/2022Morgan StanleyLower TargetEqual Weight$617.00 ➝ $585.00
1/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform$675.00 ➝ $575.00
1/3/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$660.00
12/15/2021Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$660.00
12/14/2021Leerink PartnersReiterated RatingBuy
12/13/2021HC WainwrightReiterated RatingBuy
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$750.00
12/7/2021CowenInitiated CoverageMarket Perform$625.00
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$824.00
11/19/2021BMO Capital MarketsInitiated CoverageOutperform$780.00
11/10/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$700.00 ➝ $760.00
11/5/2021Leerink PartnersBoost TargetOutperform$798.00 ➝ $850.00
11/5/2021Morgan StanleyBoost TargetEqual Weight$571.00 ➝ $617.00
11/5/2021BenchmarkDowngradeBuy ➝ Hold
11/5/2021HC WainwrightBoost TargetBuy$842.00 ➝ $844.00
10/26/2021Leerink PartnersBoost TargetOutperform$785.00 ➝ $798.00
10/22/2021HC WainwrightBoost TargetBuy$831.00 ➝ $842.00
10/12/2021Morgan StanleyLower TargetEqual Weight$606.00 ➝ $571.00
10/4/2021HC WainwrightReiterated RatingBuy$831.00
9/21/2021BMO Capital MarketsBoost TargetOutperform$669.00 ➝ $706.00
9/15/2021Piper SandlerBoost TargetOverweight$675.00 ➝ $690.00
9/15/2021Cantor FitzgeraldBoost TargetOverweight$670.00 ➝ $700.00
9/15/2021HC WainwrightBoost TargetBuy$787.00 ➝ $831.00
9/9/2021UBS GroupInitiated CoverageBuy$763.00
9/7/2021Morgan StanleyBoost TargetEqual Weight$576.00 ➝ $606.00
8/23/2021BenchmarkBoost TargetBuy$636.00 ➝ $727.00
8/20/2021HC WainwrightReiterated RatingBuy$787.00
8/6/2021BarclaysBoost TargetOverweight$675.00 ➝ $705.00
8/6/2021Leerink PartnersBoost TargetOutperform$641.00 ➝ $725.00
8/6/2021BMO Capital MarketsBoost TargetOutperform$625.00 ➝ $669.00
8/6/2021OppenheimerBoost TargetOutperform$725.00 ➝ $825.00
8/5/2021Piper SandlerBoost TargetOverweight$650.00 ➝ $675.00
8/2/2021HC WainwrightBoost TargetBuy$729.00 ➝ $741.00
7/23/2021Royal Bank of CanadaBoost TargetSector Perform$629.00 ➝ $679.00
7/8/2021BenchmarkBoost TargetBuy$590.00 ➝ $636.00
6/29/2021HC WainwrightInitiated CoverageBuy$703.00
5/7/2021Leerink PartnersLower TargetOutperform$657.00 ➝ $641.00
5/7/2021Morgan StanleyBoost TargetEqual Weight$477.00 ➝ $495.00
4/19/2021Morgan StanleyLower TargetEqual Weight$525.00 ➝ $477.00
4/13/2021Robert W. BairdReiterated RatingHold
3/26/2021Leerink PartnersBoost TargetOutperform$655.00 ➝ $657.00
2/23/2021Credit Suisse GroupBoost TargetOutperform$753.00 ➝ $760.00
2/16/2021Cantor FitzgeraldLower TargetOverweight$696.00 ➝ $656.00
2/8/2021Morgan StanleyLower TargetEqual Weight$553.00 ➝ $525.00
2/8/2021Credit Suisse GroupLower TargetOutperform$758.00 ➝ $753.00
2/8/2021CowenLower TargetOutperform$684.00 ➝ $565.00
2/8/2021Leerink PartnersBoost TargetOutperform$623.00 ➝ $640.00
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$630.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$527.00 ➝ $553.00
1/14/2021Smith Barney CitigroupBoost Target$575.00 ➝ $584.00
1/13/2021BenchmarkUpgradeHold ➝ Buy$590.00
1/8/2021FIXUpgradeNeutral ➝ Buy$635.00 ➝ $575.00
12/16/2020Morgan StanleyLower TargetEqual Weight$602.00 ➝ $527.00
12/16/2020Credit Suisse GroupLower TargetOutperform$737.00 ➝ $736.00
11/9/2020Morgan StanleyLower TargetEqual Weight$609.00 ➝ $602.00
11/6/2020Truist FinancialBoost Target$750.00 ➝ $770.00
11/6/2020Credit Suisse GroupLower TargetOutperform$745.00 ➝ $737.00
11/6/2020Leerink PartnersBoost TargetOutperform$650.00 ➝ $653.00
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$626.00 ➝ $630.00
10/13/2020Morgan StanleyLower TargetEqual Weight$611.00 ➝ $609.00
10/6/2020Leerink PartnersBoost TargetOutperform$629.00 ➝ $650.00
10/5/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$690.00
10/1/2020JPMorgan Chase & Co.Reiterated RatingHold
8/20/2020BenchmarkDowngradeBuy ➝ Hold
8/7/2020Credit Suisse GroupBoost TargetOutperform$716.00 ➝ $725.00
8/6/2020BarclaysBoost Target$615.00 ➝ $675.00
8/6/2020Morgan StanleyLower TargetEqual Weight$619.00 ➝ $611.00
8/6/2020OppenheimerBoost TargetOutperform$675.00 ➝ $725.00
8/6/2020CitigroupBoost TargetNeutral$585.00 ➝ $635.00
8/6/2020BMO Capital MarketsBoost TargetOutperform$525.00 ➝ $626.00
8/5/2020The Goldman Sachs GroupBoost Target$700.00 ➝ $800.00
8/5/2020Piper SandlerBoost TargetOverweight$630.00 ➝ $675.00
7/20/2020Credit Suisse GroupBoost TargetOutperform$700.00 ➝ $716.00
7/15/2020Morgan StanleyBoost TargetEqual Weight$555.00 ➝ $619.00
7/8/2020SunTrust BanksUpgradeHold ➝ Buy$400.00 ➝ $750.00
7/1/2020OppenheimerBoost TargetOutperform$625.00 ➝ $675.00
6/24/2020Credit Suisse GroupBoost TargetOutperform$605.00 ➝ $700.00
6/12/2020Jefferies Financial GroupBoost TargetBuy$657.00 ➝ $691.00
6/2/2020Jefferies Financial GroupReiterated RatingBuy$657.00
6/2/2020CowenReiterated RatingHold$584.00
6/2/2020OppenheimerReiterated RatingBuy$625.00
6/2/2020Cantor FitzgeraldBoost TargetNeutral$400.00 ➝ $624.00
5/28/2020BarclaysBoost Target$530.00 ➝ $615.00
5/27/2020CfraLower TargetHold$557.00 ➝ $549.00
5/27/2020Leerink PartnersBoost TargetOutperform$622.00 ➝ $625.00
5/26/2020Leerink PartnersReiterated RatingBuy$622.00
5/26/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$559.00 ➝ $734.00
5/6/2020Robert W. BairdBoost TargetNeutral ➝ Neutral$487.00 ➝ $510.00
5/6/2020BMO Capital MarketsBoost TargetMarket Perform$466.00 ➝ $525.00
5/6/2020Royal Bank of CanadaLower Target$533.00 ➝ $524.00
5/6/2020Piper SandlerBoost Target$550.00 ➝ $600.00
5/6/2020Morgan StanleyBoost TargetEqual Weight$409.00 ➝ $555.00
5/6/2020OppenheimerBoost TargetOutperform$525.00 ➝ $625.00
5/6/2020Credit Suisse GroupBoost TargetOutperform$596.00 ➝ $605.00
5/6/2020The Goldman Sachs GroupBoost TargetConviction-Buy$636.00 ➝ $700.00
5/6/2020Leerink PartnersBoost TargetOutperform$604.00 ➝ $622.00
5/1/2020Piper SandlerReiterated RatingOverweight
4/28/2020CitigroupDowngradeBuy ➝ Neutral$540.00 ➝ $575.00
4/19/2020BenchmarkInitiated CoverageHold
4/17/2020BMO Capital MarketsBoost TargetMarket Perform$379.00 ➝ $466.00
4/17/2020BenchmarkUpgradeHold ➝ Buy$655.00
4/15/2020Morgan StanleyLower TargetEqual Weight$410.00 ➝ $409.00
4/15/2020JPMorgan Chase & Co.Boost TargetNeutral$375.00 ➝ $429.00
4/8/2020BenchmarkInitiated CoverageHold
4/7/2020Leerink PartnersBoost TargetOutperform$600.00 ➝ $604.00
4/6/2020Wells Fargo & CompanyBoost TargetEqual Weight$370.00 ➝ $435.00
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$455.00
(Data available from 3/27/2020 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 21 very positive mentions
  • 38 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
8/29/2024
  • 42 very positive mentions
  • 45 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2024
  • 34 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
10/28/2024
  • 69 very positive mentions
  • 37 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
11/27/2024
  • 54 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
12/27/2024
  • 53 very positive mentions
  • 99 positive mentions
  • 15 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2025
  • 123 very positive mentions
  • 130 positive mentions
  • 15 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2025
  • 130 very positive mentions
  • 79 positive mentions
  • 11 negative mentions
  • 3 very negative mentions
Mentions as of
3/27/2025

Current Sentiment

  • 130 very positive mentions
  • 79 positive mentions
  • 11 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $640.14
Low: $629.02
High: $644.00

50 Day Range

MA: $685.91
Low: $634.14
High: $744.83

52 Week Range

Now: $640.14
Low: $629.02
High: $1,211.20

Volume

1,251,813 shs

Average Volume

637,613 shs

Market Capitalization

$69.98 billion

P/E Ratio

16.72

Dividend Yield

0.13%

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: Argus, Bank of America Co., Barclays PLC, Bernstein Bank, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for REGN.

What is the current price target for Regeneron Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $973.13, suggesting a possible upside of 52.0%. Guggenheim has the highest price target set, predicting REGN will reach $1,300.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $165.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has 1 sell rating, 6 hold ratings, 16 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for REGN.

What other companies compete with Regeneron Pharmaceuticals?

Other companies that are similar to Regeneron Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Alnylam Pharmaceuticals and Biogen. Learn More about companies similar to Regeneron Pharmaceuticals.

How do I contact Regeneron Pharmaceuticals' investor relations team?

Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is (914) 847-7000 and its investor relations email address is invest@regeneron.com. The official website for Regeneron Pharmaceuticals is www.regeneron.com. Learn More about contacing Regeneron Pharmaceuticals investor relations.